ERNA
Ernexa Therapeutics Inc. · NASDAQ
$1.98-0.11 (-5.26%)today
Alert me next time ERNA moves like this- Market cap
- $2.8M
- Prev close
- $2.09
52-week rangeAt the low
$1.91$37.75
Ernexa Therapeutics Inc. (ERNA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for ERNA, including 1 press release or news item, 1 SEC filing and 1 13D/G filing. The most recent was published Nov 10, 2026.
Price$1.98-2.23 (-52.97%)
2026-08-132026-11-13
Financial highlights
Full financials- Net income, TTM
- -$13.96M
- Free cash flow, TTM
- -$10.75M
- Cash
- $5.58M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks37-71%
2026-05-242026-11-15
Mix2490d
- Other8(33%)
- Insider8(33%)
- SEC Filings4(17%)
- Leadership2(8%)
- Market1(4%)
- 13D/G1(4%)
Activity · 52 weeks7254 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Ernexa Therapeutics Inc.SCHEDULE 13G/A - Ernexa Therapeutics Inc. (0000748592) (Subject)
- SECSEC Form 10-Q filed by Ernexa Therapeutics Inc.10-Q - Ernexa Therapeutics Inc. (0000748592) (Filer)
- PRErnexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” SegmentLeadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation Discussion features Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer Access the segment here CAMBRIDGE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the release of a new Virtual Investor "What This Means" segm
- SECSEC Form 8-K filed by Ernexa Therapeutics Inc.8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)
- PRErnexa Therapeutics to Participate in Virtual Investor Closing Bell SeriesLive video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer, on Thursday, October 15th at 4:00 PM ET Register here CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, member of Ernexa’s Scientific Advisory Board, and developer of the technology underlying Ernexa’s platfo
- PRErnexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer CenterCAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that new preclinical data from its lead oncology program, ERNA-101, have been selected for a Flash Talk presentation at the Next-Generation Cancer Therapeutics meeting, co-hosted by Nature Conferences and The University of Texas MD Anderson Cancer Center. The meeting will take place October 6–8, 2026, on MD Anderson’s campus in Houston, Texas. The presentation will highlight ERNA-101’s potential to address a fundamental challenge in ovarian cancer: the immunosuppressive tumor microenvironment tha
- PRErnexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the ClinicCEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1 Discussion Highlights ERNA-101’s Near-Term Milestones and Broader Potential Across Difficult-to-Treat Solid Tumors Access the Ernexa CEO Corner here CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today released a new installment of its CEO Corner series featuring President and Chief Executive Officer Sanjeev Luther. The discussion
- PRErnexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 INDRepeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release No teratoma formation observed in ERNA-101-treated animals through the six-month tumorigenicity in-life phase, addressing a fundamental safety consideration for an iPSC-derived cell therapy Biodistribution study showed no significant ERNA-101 signal in tumor-free animals or non-tumor tissues, supporting ERNA-101’s tumor-homing delivery strategy Encouraging safety results build on previously reported complete tumor clearance and durable survival in ovarian
- PRErnexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology StrategyErnexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector President & CEO Sanjeev Luther to deliver an Innovation Spotlight presentation on October 6, 2026, at 1:30 PM Presentation to highlight Ernexa’s focused oncology strategy, beginning with ERNA-101 in platinum-resistant ovarian cancer and its potential for broader expansion across ovarian cancer and other solid tumor indications Differentiated synthetic iMSC platform designed to provide a scalable, off-the-shelf treatment solution without the need for patient-specific cell harvesting ERNA-101 remains on track for planned IND submission in 2026 CAMBRIDGE, Mass., Sep
- INSIDERSEC Form 3 filed by new insider Spiegel Robert J.3 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
- PRErnexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of DirectorsDr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics Appointment further strengthens Ernexa’s Board as the Company advances ERNA-101 toward clinical development CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the appointment of Robert J. Spiegel, M.D., FACP, to its Board of Directors. Dr. Spiegel is an accomplished physician, biopharmaceutical executive and drug developer with decades of experience spanni
- SECErnexa Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)
- SECErnexa Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)
- PRErnexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human DosingERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC platform beyond oncology Positive ERNA-201 findings add to a growing body of preclinical evidence supporting the versatility of Ernexa's synthetic iMSC platform and its ability to deliver engineered therapeutic factors in disease Company is concentrating near-term resources on ERNA-101 while broadening its oncology strategy and advancing next-generation iMSC candidates across additional high-need cancer indications ERNA-201 remains an important platform asset with demonstrated preclinical proof
- PRErnexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferencePresident and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET Management available for one-on-one meetings with investors during the conference CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16, 2026, in New York City. During the presentation, Mr. Luther will provide an overview of Ernexa’s focused oncology strategy and recent progress with ERNA-10
- INSIDERSEC Form 4 filed by Director Bristol James Arthur4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
- INSIDERSEC Form 4 filed by Director Cicala Peter4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
- INSIDERSEC Form 4 filed by Director Wexler William A.4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
- INSIDERSEC Form 4 filed by Director Polinsky David4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
- INSIDERSEC Form 4 filed by Director Ratner Elena4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Luther Sanjeev4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
- INSIDERNew insider Polinsky David claimed ownership of 8,000 shares (SEC Form 3)3 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
- NEWSJTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOsNine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming catalysts and the opportunities management believes investors should be watching todayAccess on demand conference here FRENCHTOWN, NJ / ACCESS Newswire / August 27, 2026 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the release of its Virtual Investor "Why Now" On-Demand Conference, featuring a fast-paced series of 60-second presentations from the CEOs of nine publicly traded companies.The premise is simple: Why sho
- PRErnexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand ConferenceVideo webcast now available here CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes now is a pivotal time for Ernexa. The pitch discusses the Company’s planned transition into a clinical-stage biotechnology company, with lead candidate ERNA-101 advancing toward a planned Investig
- PRErnexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical StageSeasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance Appointment further strengthens leadership team at a pivotal inflection point as Company positions ERNA-101 for planned IND submission in Q3 2026 and Phase 1 clinical study initiation in the Q4 2026 CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of David Polinsky to its Board of Directors, further strengthening the Company's leader
ERNA FAQ
7 questionsWhat is the latest news on ERNA?
In the last 30 days Quantisnow tracked 3 wire items for ERNA: 1 press release or news item, 1 SEC filing and 1 13D/G filing. The most recent was published on November 10, 2026.Is ERNA profitable?
No. Ernexa Therapeutics Inc. reported a net loss of $13.96M for the twelve months ended Sep 30, 2026.How much cash and debt does ERNA have?
Ernexa Therapeutics Inc. reported $5.58M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does ERNA stock trade?
Ernexa Therapeutics Inc. (ERNA) is listed on NASDAQ.What sector and industry is ERNA in?
Ernexa Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to ERNA?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare ERNA side-by-side with any of them on Quantisnow.How can I track ERNA on Quantisnow?
Quantisnow aggregates Ernexa Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ERNA to receive live email and push alerts on every new disclosure.